Recruiting Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL. NCT04771572 Conditions Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, Blood Protein Disorders, +48 more Locations University of Chicago — Chicago, Illinois, United States Dana Farber Cancer Institute — Boston, Massachusetts, United States University of North Carolina — Chapel Hill, North Carolina, United States Cincinnati Children's Hospital Medical Center — Cincinnati, Ohio, United States View more locations Show fewer locations Loading locations... View Trial Details
